Compare BCC & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCC | CLDX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | 7680 | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2012 | 1995 |
| Metric | BCC | CLDX |
|---|---|---|
| Price | $70.05 | $29.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $99.20 | $46.60 |
| AVG Volume (30 Days) | 367.4K | ★ 692.1K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $4,995,290,000.00 | $12,743,000.00 |
| Revenue This Year | $3.41 | $111.39 |
| Revenue Next Year | $4.76 | $235.85 |
| P/E Ratio | $140.02 | ★ N/A |
| Revenue Growth | 12.71 | ★ 87.78 |
| 52 Week Low | $65.00 | $19.52 |
| 52 Week High | $95.00 | $35.83 |
| Indicator | BCC | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 40.54 |
| Support Level | $68.93 | $28.55 |
| Resistance Level | $72.31 | $30.90 |
| Average True Range (ATR) | 2.03 | 1.04 |
| MACD | 0.47 | -0.20 |
| Stochastic Oscillator | 82.23 | 22.48 |
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.